Triple or Quadruple Combination DAAs Treatment for Subjects With HCV GT 1b Infection
Status:
Withdrawn
Trial end date:
2020-04-30
Target enrollment:
Participant gender:
Summary
This is a phase 2a, open-label, randomized study. The study is designed to test the
hypothesis that the nucleoside inhibitor sofosbuvir combined with NS5A inhibitor daclatasvir
and NS5B non-nucleoside inhibitor CDI-31244 with/without the protease inhibitor asunaprevir
will result in high SVR rate with a shortened treatment duration (2 weeks) in non-cirrhotic
HCV genotype 1b-infected subjects.